TrialDiabetes, obesity & metabolism2020

The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.

Jonathan M Wilson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.